U.S. drugmaker makes progress on weekly insulin shot as Danish competitor stumbles: WSJ

NEW YORK, Sept. 5 (Xinhua) -- U.S. drugmaker Eli Lilly announced more progress toward a once-weekly insulin shot, weeks after its Danish competitor Novo Nordisk encountered a significant setback with a similar product, reported The Wall Street Journal (WSJ) on Thursday.

Lilly, Novo, and French pharmaceutic company Sanofi dominate the global market for insulin, a lifesaving medicine for patients with diabetes. While the new GLP-1 medicines, Lilly's Zepbound and Novo's Wegovy, may eventually cut into demand for insulin, it remains an essential medicine, and a major product for the three manufacturers.